NCT00101179View on ClinicalTrials.gov

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

November 3, 2004

Primary Completion Date

April 20, 2011

Study Completion Date

February 3, 2014

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromeLeukemiaMyelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic Syndrome
Interventions
DRUG

Azacitidine

Given SC

DRUG

Entinostat

Given orally

Trial Locations (3)

10029

Mount Sinai Hospital, New York

10065

Memorial Sloan Kettering Cancer Center, New York

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00101179 - MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter